Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

Vaccination and Household Transmission of SARS-CoV-2 In this study involving household
contacts of persons with laboratory-confirmed Covid-19, the risk of household transmission …

Background There are few primary care studies of the COVID-19 pandemic. We aimed to
identify demographic and clinical risk factors for testing positive for severe acute respiratory …

Background Knowledge of the age-specific prevalence of immunity from, and incidence of
infection with, 2009 pandemic influenza A H1N1 virus is essential for modelling the future …

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has
successfully controlled the incidence of serogroup C disease, as a result of high short-term …

Background In October, 2012, a pertussis vaccination programme for pregnant women was
introduced in response to an outbreak across England. We aimed to assess the vaccine …

Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

Background The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine
escape and high transmissibility, with early studies indicating lower severity of infection …

Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …

Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …